MTHFR C677T variant reduces risk of sporadic Parkinson's disease in ethnic chinese

Acta Neurologica Scandinavica

Volumn 130, Issue 1, 2014, Pages

  Liao, Q ^a   Li, N N ^a   Mao, X Y ^a   Chang, X L ^a   Zhao, D M ^a   Zhang, J H ^b   Yu, W J ^a   Tan, E K ^c,d   Peng, R ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

MTHFR C677T; Parkinson's disease; SNP

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAN CHINESE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; CHINA; GENETIC PREDISPOSITION; GENETICS; MASS SPECTROMETRY; MIDDLE AGED; RISK; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84902110603     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12245     Document Type: Article

References (29)

1. Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M. Missing pieces in the Parkinson disease puzzle. Nat Med 2010;16:653-61.
2. Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol 2008;14:14-20.
3. Sundal C, Fujioka S, Uitti RJ, Wszolek ZK. Autosomal dominant Parkinson's disease. Parkinsonism Relat Disord 2012;18:7-10.
4. Crosiers D, Theuns J, Cras P, van Broeckhoven C. Parkinson disease: insights in clinical, genetic and pathological features of monogenic disease subtypes. J Chem Neuroanat 2011;42:131-41.
5. Sharp L, Little J. Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. Am J Epidemiol 2004;159:423-43.
6. Chango A, Boisson F, Barbé F, Quilliot D, Droesch S, Pfister M. The effect of 677C→T and 1298A→C mutations on plasma homocysteine and 5, 10-methylenetetrahydrofolate reductase activity in healthy subjects. Br J Nutr 2000;83:593-6.
7. Zhu ZG, Ai QL, Wang WM, Xiao ZC. Meta-analysis supports association of a functional SNP (rs1801133) in the MTHFR gene with Parkinson's disease. Gene 2013;531:78-83.
8. Wu YL, Ding XX, Sun YH, Yang HY, Sun L. Methylenetetrahydrofolate reductase (MTHFR) C677T/A1298C polymorphisms and susceptibility to Parkinson's disease: a meta-analysis. J Neurol Sci 2013;335:14-21.
9. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
10. Dupont WD, Plummer WDJR. Power and sample size calculations. A review and computer program. Control Clin Trials 1990;11:116-28.
11. Gorgone G, Currò M, Ferlazzo N et al. Coenzyme Q10, hyperhomocysteinemia and MTHFR C677T polymorphism in levodopa-treated Parkinson's disease patients. Neuromolecular Med 2012;14:84-90.
12. Fong CS, Shyu HY, Shieh JC, Fu YP, Chin TY, Wang HW. Association of MTHFR, MTR, and MTRR polymorphisms with Parkinson's disease among ethnic Chinese in Taiwan. Clin Chim Acta 2011;412:332-8.
13. Woitalla D, Kuhn W, Müller T. MTHFR C677T polymorphism, folic acid and hyperhomocysteinemia in levodopa treated patients with Parkinson's disease. J Neural Transm Suppl 2004;68:15-20.
14. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001;22:195-201.
15. Zoccolella S, Martino D, Defazio G, Lamberti P, Livrea P. Hyperhomocysteinemia in movement disorders: current evidence and hypotheses. Curr Vasc Pharmacol 2006;4:237-43.
16. Imamura K, Takeshima T, Nakaso K, Nakashima K. Homocysteine is toxic for dopaminergic neurons in primary mesencephalic culture. NeuroReport 2007;18:1319-22.
17. Greenamyre JT, Hastings TG. Biomedicine. Parkinson's-divergent causes, convergent mechanisms. Science 2004;304:1120-2.
18. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 2002;80:101-10.
19. Nakaso K, Yasui K, Kowa H, Kusumi M, Ueda K, Yoshimoto Y. Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype. J Neurol Sci 2003;207:19-23.
20. Kruman II, Culmsee C, Chan SL et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000;20:6920-6.
21. Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 2003;26:137-46.
22. Religa D, Czyzewski K, Styczynska M, Peplonska B, Lokk J, Chodakowska-Zebrowska M. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. Neurosci Lett 2006;404:56-60.
23. Dorszewska J, Florczak J, Rozycka A, Kempisty B, Jaroszewska-Kolecka J, Chojnacka K. Oxidative DNA damage and level of thiols as related to polymorphisms of MTHFR, MTR, MTHFD1 in Alzheimer's and Parkinson's diseases. Acta Neurobiol Exp 2007;67:113-29.
24. Bialecka M, Kurzawski M, Roszmann A et al. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease. Pharmacogenet Genomics 2012;22:716-24.
25. Caccamo D, Gorgone G, Currò M, Parisi G, di Iorio W, Menichetti C. Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients. Neuromolecular Med 2007;9:249-54.
26. Lin JJ, Yueh KC, Liu CS, Liu JT, Lin SZ. 5, 10-methylenetetrahydrofolate reductase C677T gene polymorphism can influence age at onset of Parkinson's disease. Acta Neurol Taiwan 2007;16:150-7.
27. Yuan RY, Sheu JJ, Yu JM et al. Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients. J Neurol Sci 2009;287:64-8.
28. Todorović Z, Dzoljić E, Novaković I, Mirković D, Stojanović R, Nesić Z. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. J Neurol Sci 2006;248:56-61.
29. Harmon DL, Ramsbottom D, Whitehead AS, Ben-Shlomo Y, Davey-Smith G. The thermolabile variant of 5, 10-methylenetetrahydrofolate reductase is not associated with Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:671.